Aptevo Therapeutics Stock Is Sinking Today - Here ' s Why

Aptevo Therapeutics Inc APVO announced that its bispecific acute myelogenous leukemia (AML) drug candidate APVO436, in combination with venetoclax and azacitidine, achieved positive duration of remission results in its Phase 1b dose-escalation trial. High response rate observed: 82% (9/11) of…#aml #durationofremission #dor #phase2 #1h24 #apvo
Source: Reuters: Health - Category: Consumer Health News Source Type: news